{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:08:24Z","timestamp":1789636104535,"version":"4.0.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.coi.2019.07.011","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T17:51:45Z","timestamp":1567187505000},"page":"46-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Antigen-specific tolerance to self-antigens in protein replacement therapy, gene therapy and autoimmunity"],"prefix":"10.1016","volume":"61","author":[{"given":"Lawrence","family":"Steinman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy P","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Utz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Villoslada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2019.07.011_bib0005","series-title":"Mountain Interval","author":"Frost","year":"1916"},{"key":"10.1016\/j.coi.2019.07.011_bib0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1017\/S0022172400008172","article-title":"Duration of passive immunity","volume":"22","author":"Glenny","year":"1923","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.coi.2019.07.011_bib0015","first-page":"509","article-title":"The dosage requirements for immunological paralysis by soluble proteins","volume":"15","author":"Mitchison","year":"1968","journal-title":"Immunology"},{"key":"10.1016\/j.coi.2019.07.011_bib0020","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(77)90871-6","article-title":"Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder","volume":"2","author":"Brackmann","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2019.07.011_bib0025","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12918-014-0120-4","article-title":"Autoimmunity and tumor immunology: two facets of a probabilistic immune system","volume":"8","author":"Iranzo","year":"2014","journal-title":"BMC Syst Biol"},{"key":"10.1016\/j.coi.2019.07.011_bib0030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006103","article-title":"Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8(+) T cells in type 1 diabetes","volume":"5","author":"Roep","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2019.07.011_sbref0035","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf7779","article-title":"Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes","volume":"9","author":"Alhadj Ali","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2019.07.011_bib0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(11)60895-7","article-title":"Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial","volume":"378","author":"Wherrett","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2019.07.011_bib0045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1107096","article-title":"GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus","volume":"366","author":"Ludvigsson","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2019.07.011_sbref0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-8587(18)30109-8","article-title":"Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine","volume":"7","author":"Roep","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.coi.2019.07.011_bib0055","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.coi.2019.07.011_sbref0060","doi-asserted-by":"crossref","DOI":"10.1111\/hae.13762","article-title":"Future of immunotolerance treatment G: the changing face of immune tolerance induction in haemophilia A with the advent of emicizumab","author":"Carcao","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.coi.2019.07.011_bib0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/hae.13413","article-title":"Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis","volume":"24","author":"Carcao","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.coi.2019.07.011_sbref0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2019.07.011_sbref0075","doi-asserted-by":"crossref","first-page":"E9182","DOI":"10.1073\/pnas.1808648115","article-title":"Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy","volume":"115","author":"Ho","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2019.07.011_bib0080","doi-asserted-by":"crossref","first-page":"9652","DOI":"10.1073\/pnas.1813461115","article-title":"Building immune tolerance through DNA vaccination","volume":"115","author":"Parks","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2019.07.011_bib0085","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1177\/1352458515581441","article-title":"The re-emergence of antigen-specific tolerance as a potential therapy for MS","volume":"21","author":"Steinman","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.coi.2019.07.011_bib0090","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.0105-2896.2005.00280.x","article-title":"Oral tolerance","volume":"206","author":"Faria","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coi.2019.07.011_bib0095","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1126\/science.7680493","article-title":"Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis","volume":"259","author":"Weiner","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.coi.2019.07.011_bib0100","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0b013e318233b240","article-title":"A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS","volume":"77","author":"Freedman","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.coi.2019.07.011_bib0105","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/80516","article-title":"Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand","volume":"6","author":"Bielekova","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2019.07.011_bib0110","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/80525","article-title":"Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group","volume":"6","author":"Kappos","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2019.07.011_bib0115","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/80424","article-title":"Specific immunotherapy: one size does not fit all","volume":"6","author":"Genain","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2019.07.011_bib0120","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/85266","article-title":"An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide","volume":"2","author":"Pedotti","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2019.07.011_bib0125","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1212\/WNL.0000000000005118","article-title":"Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis","volume":"90","author":"Chataway","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.coi.2019.07.011_bib0130","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000093","article-title":"Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS","volume":"2","author":"Streeter","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.coi.2019.07.011_bib0135","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/ana.22219","article-title":"Immune regulation of multiple sclerosis by transdermally applied myelin peptides","volume":"68","author":"Jurynczyk","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coi.2019.07.011_bib0140","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2013.3022","article-title":"Transdermal application of myelin peptides in multiple sclerosis treatment","volume":"70","author":"Walczak","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.coi.2019.07.011_bib0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006168","article-title":"Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis","volume":"5","author":"Lutterotti","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2019.07.011_sbref0150","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1073\/pnas.1820039116","article-title":"Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial","volume":"116","author":"Zubizarreta","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2019.07.011_bib0155","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/375798a0","article-title":"The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis","volume":"375","author":"van Noort","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.coi.2019.07.011_bib0160","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/375739b0","article-title":"Multiple sclerosis. Presenting an odd autoantigen","volume":"375","author":"Steinman","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.coi.2019.07.011_bib0165","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature05935","article-title":"Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination","volume":"448","author":"Ousman","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.coi.2019.07.011_bib0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143366","article-title":"Therapeutic intervention in multiple sclerosis with Alpha B-crystallin: A Randomized Controlled Phase IIa Trial","volume":"10","author":"van Noort","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2019.07.011_bib0175","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/archneur.64.10.nct70002","article-title":"Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1\/2 trial","volume":"64","author":"Bar-Or","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.coi.2019.07.011_bib0180","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ana.21370","article-title":"Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis","volume":"63","author":"Garren","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coi.2019.07.011_bib0185","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41587-019-0015-4","article-title":"Antigen-specific therapeutic approaches for autoimmunity","volume":"37","author":"Serra","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coi.2019.07.011_bib0190","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2017.17070","article-title":"Effect of oral insulin on prevention of diabetes in relatives of patients with Type 1 diabetes: a randomized clinical trial","volume":"318","author":"Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study G","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.coi.2019.07.011_sbref0195","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, Teplizumab, in relatives at risk for Type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2019.07.011_bib0200","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(11)60931-8","article-title":"Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial","volume":"378","author":"Sherry","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2019.07.011_bib0205","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.2337\/db13-0236","article-title":"Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial","volume":"62","author":"Hagopian","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.coi.2019.07.011_bib0210","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0041-1345(98)00278-4","article-title":"Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience","volume":"30","author":"Woodle","year":"1998","journal-title":"Transplant Proc"},{"key":"10.1016\/j.coi.2019.07.011_bib0215","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.4049\/jimmunol.171.9.4920","article-title":"An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems","volume":"171","author":"Ho","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2019.07.011_bib0220","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9391845","article-title":"Intralymphatic glutamic acid decarboxylase-alum administration induced Th2-like-specific immunomodulation in responder patients: a pilot clinical trial in Type 1 diabetes","volume":"2018","author":"Tavira","year":"2018","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.coi.2019.07.011_bib0225","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2172-4-2","article-title":"Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus","volume":"4","author":"Pedotti","year":"2003","journal-title":"BMC Immunol"},{"key":"10.1016\/j.coi.2019.07.011_bib0230","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.4049\/jimmunol.162.6.3336","article-title":"Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation","volume":"162","author":"Ruiz","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2019.07.011_bib0235","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fimmu.2013.00053","article-title":"The nature of activatory and tolerogenic dendritic cell-derived signal II","volume":"4","author":"Bakdash","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2019.07.011_bib0240","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature03727","article-title":"Design of effective immunotherapy for human autoimmunity","volume":"435","author":"Feldmann","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.coi.2019.07.011_bib0245","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1073\/pnas.1701746114","article-title":"Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease","volume":"114","author":"Pishesha","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2019.07.011_bib0250","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1073\/pnas.1216353110","article-title":"Engineering antigens for in situ erythrocyte binding induces T-cell deletion","volume":"110","author":"Kontos","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2019.07.011_bib0255","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nm0797-797","article-title":"Identification of tissue transglutaminase as the autoantigen of celiac disease","volume":"3","author":"Dieterich","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2019.07.011_bib0260","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S2468-1253(17)30110-3","article-title":"Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies","volume":"2","author":"Goel","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2019.07.011_sbref0265","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ebiom.2017.11.018","volume":"26","author":"Daveson","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.coi.2019.07.011_bib0270","series-title":"ImmusanT Discontinues Phase 2 Clinical Trial for Nexvax2 in Patients with Celiac Disease","author":"Immusan","year":"2019"},{"key":"10.1016\/j.coi.2019.07.011_bib0275","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/jamaneurol.2013.3553","article-title":"The road not taken: antigen-specific therapy and neuroinflammatory disease","volume":"70","author":"Steinman","year":"2013","journal-title":"JAMA Neurol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791519300603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791519300603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:35:34Z","timestamp":1763642134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791519300603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":55,"alternative-id":["S0952791519300603"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2019.07.011","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antigen-specific tolerance to self-antigens in protein replacement therapy, gene therapy and autoimmunity","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2019.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}